LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting
“We continue to advance our understanding of the GeneRide™ platform and are especially pleased to be sharing encouraging preclinical data on a novel methylmalonic acidemia model at this year’s virtual ASGCT meeting,” said
Oral Presentation
Title: Treatment of Juvenile Mice with Methylmalonic Acidemia (MMA) by Targeted Integration of MMUT into Albumin Using a Promoterless AAV Vector
Presenter:
Session Title: Genome Editing in Inborn Errors of Metabolism
Session Date/Time:
Presentation Time:
Abstract Number: 963
Poster Presentations
Title: Durable and Efficacious Transgene Expression Driven by GeneRide in Liver Injury Models
Session Title: Gene Targeting and Gene Correction
Session Date/Time:
Abstract Number: 208
Title: Developing a Potency Assay for AAV-Based Genome Editing Vectors
Session Title: Vector and Cell Engineering, Production or Manufacturing
Session Date/Time:
Abstract Number: 434
Title: AAV Development Program: Towards the Next Generation of Human Livertropic AAV Variants
Session Title: AAV Vectors - Virology and Vectorology
Session Date/Time:
Abstract Number: 564
Title: Nuclease-Free Glucose-6-Phosphatase-α Gene Integration Ameliorates Hypoglycemia in Glycogen Storage Disease Type Ia
Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
Session Date/Time:
Abstract Number: 682
Title: GeneRide-Encoding hUGT1A1 Rescues Phenotypes of a Mouse Model of Crigler-Najjar Syndrome
Session Title: Gene Targeting and Gene Correction
Session Date/Time:
Abstract Number: 1049
Additional information on the meeting can be found on the ASGCT website: https://annualmeeting.asgct.org/am20/
About
For more information, please visit www.logicbio.com.
Forward Looking Statements
This press release contains “forward-looking” statements within the meaning of the federal securities laws. These are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development activities and preclinical studies and potential future clinical trials. These risks are discussed in the Company’s filings with the
Contacts:
Associate Director, Investor Relations
bluque@logicbio.com
951-206-1200
Source: LogicBio Therapeutics